177Lu- labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts-Reference-Cited by-同舟云学术

177Lu- labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts

Published:2009-10 Issue:7 Volume:36 Page:759-770
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Zacchetti Alberto,Coliva Angela,Luison Elena,Seregni Ettore,Bombardieri Emilio,Giussani Augusto,Figini Mariangela,Canevari Silvana

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference39 articles.

1. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care;von;Cancer,2008

2. Occult metastasis in early ovarian cancers: risk factors and associated prognosis;Ayhan;Am J Obstet Gynecol,2007

3. Epithelial ovarian cancer,1994

4. Beyond chemotherapy: targeted therapies in ovarian cancer;Yap;Nat Rev Cancer,2009

5. Anti-tumor antibodies in ovarian cancer;Luborsky;Am J Reprod Immunol,2005

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Folate-based radiotracers for nuclear imaging and radionuclide therapy;Coordination Chemistry Reviews;2022-11

2. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors;Nucleic Acid Therapeutics;2021-02-01

3. Laser photoionisation selectivity of 177Lu radionuclide for medical applications;Quantum Electronics;2019-09-01

4. Folate-targeted immunotherapies: Passive and active strategies for cancer;Cytokine & Growth Factor Reviews;2019-02

5. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer;Journal of Nuclear Medicine;2018-04-19